WuXi AppTec

WuXi AppTec Wins Third Straight EcoVadis Gold, Top 5% Globally

Shanghai – October 08, 2026 -- WuXi AppTec has secured its third consecutive Gold medal from EcoVadis, placing the pharmaceutical CRDMO among the top 5% of companies worldwide for sustainability performance.

EcoVadis scores companies across 21 criteria covering four pillars

The rating agency evaluates global supply-chain participants on Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, with Gold medals reserved for the highest percentile tier. WuXi AppTec's repeat award signals sustained compliance across its value chain rather than a one-time achievement.

Pharma CDMO Market to Hit $270.3B by 2031, Wissen Research Says

Sheridan – September 12, 2026 -- The global pharmaceutical contract development and manufacturing organization (CDMO) market is forecast to expand from $191 billion in 2026 to $270.3 billion by 2031, a compound annual growth rate of 7.2%, according to a new study by Wissen Research.

Outsourcing and biologics demand drive the growth trajectory

Pharmaceutical and biotechnology firms are increasingly outsourcing drug development and manufacturing to cut capital costs and refocus internal resources on R&D and commercialization. Demand for biologics, biosimilars, cell and gene therapies, antibody-drug conjugates, and mRNA-based medicines is pushing CDMOs to build specialized manufacturing platforms rather than remain peripheral service providers.